Cargando…
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors (TNFi) among patients with psoriasis (PsO) in a real‐world setting. Participants included adult PsO patients enrolled in the Corrona Psoriasis Registry who initiated ixekizumab, TNFi, or other IL‐17i between...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047872/ https://www.ncbi.nlm.nih.gov/pubmed/33491259 http://dx.doi.org/10.1111/dth.14808 |
_version_ | 1783679128222826496 |
---|---|
author | Lockshin, Benjamin Cronin, Angel Harrison, Ryan W. McLean, Robert R. Anatale‐Tardiff, Laura Burge, Russel Zhu, Baojin Malatestinic, William N. Atiya, Bilal Murage, Mwangi J. Gallo, Gaia Strober, Bruce Van Voorhees, Abby |
author_facet | Lockshin, Benjamin Cronin, Angel Harrison, Ryan W. McLean, Robert R. Anatale‐Tardiff, Laura Burge, Russel Zhu, Baojin Malatestinic, William N. Atiya, Bilal Murage, Mwangi J. Gallo, Gaia Strober, Bruce Van Voorhees, Abby |
author_sort | Lockshin, Benjamin |
collection | PubMed |
description | To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors (TNFi) among patients with psoriasis (PsO) in a real‐world setting. Participants included adult PsO patients enrolled in the Corrona Psoriasis Registry who initiated ixekizumab, TNFi, or other IL‐17i between 16 March 2016 to 10 August 2019 and completed ≥1 follow‐up visit. Multivariable adjusted hazard ratios (HR) were calculated to estimate the risk for drug discontinuation in the ixekizumab group relative to the other drugs. Among the 1604 drug initiations, 552 initiated ixekizumab, 450 initiated TNFi, and 602 initiated other IL‐17i. Mean age was 51 years, 49% were women, and 52% were obese (BMI > 30). Ixekizumab patients had a higher proportion of patients with PASI >12 at drug initiation (24%) than TNFi (15%) and other IL‐17i (19%). Over a median of 11 months of follow‐up, 723/1604 (45%) drug discontinuations occurred. Persistence of ixekizumab, TNFi, and other IL‐17i at 24‐months were 68%, 33%, and 46%, among biologic‐naïve patients (n = 543), and 46%, 23%, and 36%, for biologic‐experienced patients (n = 1061), respectively. Ixekizumab patients had a 64% lower risk of discontinuation vs TNFi (HR = 0.36; 95% CI 0.27‐0.47) and a 31% lower risk vs other IL‐17i (HR = 0.69, 95% CI 0.55‐0.87) after adjustment for biologic experience and other covariates. HRs were similar when limited to patients with moderate‐to‐severe PsO (BSA > 3, PASI > 3, and IGA > 1, n = 1076) at initiation. In our study of real‐world patients with PsO, initiators of ixekizumab had more prolonged drug survival than both initiators of TNFi and other IL‐17i up to 2 years of follow‐up. |
format | Online Article Text |
id | pubmed-8047872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80478722021-04-16 Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry Lockshin, Benjamin Cronin, Angel Harrison, Ryan W. McLean, Robert R. Anatale‐Tardiff, Laura Burge, Russel Zhu, Baojin Malatestinic, William N. Atiya, Bilal Murage, Mwangi J. Gallo, Gaia Strober, Bruce Van Voorhees, Abby Dermatol Ther Original Articles To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors (TNFi) among patients with psoriasis (PsO) in a real‐world setting. Participants included adult PsO patients enrolled in the Corrona Psoriasis Registry who initiated ixekizumab, TNFi, or other IL‐17i between 16 March 2016 to 10 August 2019 and completed ≥1 follow‐up visit. Multivariable adjusted hazard ratios (HR) were calculated to estimate the risk for drug discontinuation in the ixekizumab group relative to the other drugs. Among the 1604 drug initiations, 552 initiated ixekizumab, 450 initiated TNFi, and 602 initiated other IL‐17i. Mean age was 51 years, 49% were women, and 52% were obese (BMI > 30). Ixekizumab patients had a higher proportion of patients with PASI >12 at drug initiation (24%) than TNFi (15%) and other IL‐17i (19%). Over a median of 11 months of follow‐up, 723/1604 (45%) drug discontinuations occurred. Persistence of ixekizumab, TNFi, and other IL‐17i at 24‐months were 68%, 33%, and 46%, among biologic‐naïve patients (n = 543), and 46%, 23%, and 36%, for biologic‐experienced patients (n = 1061), respectively. Ixekizumab patients had a 64% lower risk of discontinuation vs TNFi (HR = 0.36; 95% CI 0.27‐0.47) and a 31% lower risk vs other IL‐17i (HR = 0.69, 95% CI 0.55‐0.87) after adjustment for biologic experience and other covariates. HRs were similar when limited to patients with moderate‐to‐severe PsO (BSA > 3, PASI > 3, and IGA > 1, n = 1076) at initiation. In our study of real‐world patients with PsO, initiators of ixekizumab had more prolonged drug survival than both initiators of TNFi and other IL‐17i up to 2 years of follow‐up. John Wiley & Sons, Inc. 2021-02-15 2021 /pmc/articles/PMC8047872/ /pubmed/33491259 http://dx.doi.org/10.1111/dth.14808 Text en © 2021 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Lockshin, Benjamin Cronin, Angel Harrison, Ryan W. McLean, Robert R. Anatale‐Tardiff, Laura Burge, Russel Zhu, Baojin Malatestinic, William N. Atiya, Bilal Murage, Mwangi J. Gallo, Gaia Strober, Bruce Van Voorhees, Abby Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry |
title | Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry |
title_full | Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry |
title_fullStr | Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry |
title_full_unstemmed | Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry |
title_short | Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry |
title_sort | drug survival of ixekizumab, tnf inhibitors, and other il‐17 inhibitors in real‐world patients with psoriasis: the corrona psoriasis registry |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047872/ https://www.ncbi.nlm.nih.gov/pubmed/33491259 http://dx.doi.org/10.1111/dth.14808 |
work_keys_str_mv | AT lockshinbenjamin drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT croninangel drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT harrisonryanw drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT mcleanrobertr drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT anataletardifflaura drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT burgerussel drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT zhubaojin drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT malatestinicwilliamn drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT atiyabilal drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT muragemwangij drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT gallogaia drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT stroberbruce drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry AT vanvoorheesabby drugsurvivalofixekizumabtnfinhibitorsandotheril17inhibitorsinrealworldpatientswithpsoriasisthecorronapsoriasisregistry |